Name | ind2118 |
---|
Description | Quinoprazine is a potent inhibitor of Vaccinia virus DNA synthesis with an IC50 value of 10 μM. Quinoprazine has antimalarial activity against Plasmodium berghei and also displays antiprion potency, significantly decreases PrPSc levels[1]-[5]. |
---|---|
Related Catalog | |
Target |
Vaccinia virus DNA synthesis[2] |
In Vitro | Quinoprazine shows antimalarial action against Plasmodium berghei, the chloroquine-resistant isolate LN-K65[1]. Quinoprazine blocks Vaccinia Virus infection by inhibiting DNA synthesis[2]. Quinoprazine (IND2118) displays good antiprion potency and inhibits baseline PrPSc with reducing rates of 76% (dividing cells) and 51% (nondividing cells), respectively. Reducing PrPSc levels by >30% is considered to have good antiprion potency[3][4]. Quinoprazine (IND2118) shows low cytotoxicity with reducing rates of 25% (dividing cells) and 24% (nondividing cells), respectively. Reducing cells <30% is considered to have a safe effect[3][4]. |
In Vivo | Quinoprazine is a 1-alkyl-4-[4-(heterylamino)phenyl]piperazines derivate, Quinoprazine (0.25 g/kg; i.p.; single dose) suppresses the growth of larvocysts of Echinococcus multilocularis in cotton rats[5]. Quinoprazine (0.2-0.5 g/kg; p.o.; single dose) acts against the adult Hymenolepis nana. Exptl. and cures infected mice radically[5]. |
References |
Molecular Formula | C25H26N4 |
---|---|
Molecular Weight | 382.50100 |
Exact Mass | 382.21600 |
PSA | 31.40000 |
LogP | 5.34940 |